Thomas Ferguson

1.9k total citations
18 papers, 374 citations indexed

About

Thomas Ferguson is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Thomas Ferguson has authored 18 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 7 papers in Cancer Research. Recurrent topics in Thomas Ferguson's work include Renal cell carcinoma treatment (9 papers), Renal and related cancers (5 papers) and Breast Cancer Treatment Studies (4 papers). Thomas Ferguson is often cited by papers focused on Renal cell carcinoma treatment (9 papers), Renal and related cancers (5 papers) and Breast Cancer Treatment Studies (4 papers). Thomas Ferguson collaborates with scholars based in Australia, United States and Canada. Thomas Ferguson's co-authors include Anna K. Nowak, Davina Ghersi, Nicholas Wilcken, Melina L Willson, Sarah Barton, Lila Zabaglo, Suzanne C. O’Neill, Mitch Dowsett, Ian Smith and Nicholas C. Turner and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Lancet Oncology.

In The Last Decade

Thomas Ferguson

15 papers receiving 361 citations

Peers

Thomas Ferguson

ONCOL

PRM

SURGE

Karen Briscoe Australia

Sandeep Sehdev Canada

T. Facchini France

O. Rixe France

Doris Augustin Germany

Rabih Said United States

Pauline du Rusquec France

Jinghong Guan China

Rebecca Shatsky United States

Manuel Chaves-Conde Spain

Karen Briscoe Australia

Thomas Ferguson

275 ×1.2

ONCOL

120 ×0.7

212 ×1.6

PRM

127 ×1.3

37 ×1.0

SURGE

Citations per year, relative to Thomas Ferguson Thomas Ferguson (= 1×) peers Karen Briscoe

Countries citing papers authored by Thomas Ferguson

Since Specialization

Citations

This map shows the geographic impact of Thomas Ferguson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Ferguson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Ferguson more than expected).

Fields of papers citing papers by Thomas Ferguson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Ferguson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Ferguson. The network helps show where Thomas Ferguson may publish in the future.

Co-authorship network of co-authors of Thomas Ferguson

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Ferguson. A scholar is included among the top collaborators of Thomas Ferguson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Ferguson. Thomas Ferguson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Albigès, Laurence, Howard Gurney, Jae‐Lyun Lee, et al.. (2025). 1Pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study. The Oncologist. 30(Supplement_2).

Voss, Martin H., Howard Gurney, Vagif Atduev, et al.. (2025). First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial. European Urology. 88(6). 614–624.

Benson, Tim, et al.. (2024). Assessment of Patient and Clinician Perspectives on Clinically Meaningful Extension of Progression-free Survival in Prostate Cancer. European Urology Open Science. 70. 175–182.

Hayne, Dickon, Pravin Viswambaram, Elizabeth Liow, et al.. (2024). The SUB ‐urothelial DUrvalumab InjEction ‐1 ( SUBDUE ‐1) trial: first‐in‐human trial in patients with bladder cancer. British Journal of Urology. 134(2). 283–290. 3 indexed citations

Choueiri, Toni K., Piotr Tomczak, Se Hoon Park, et al.. (2024). Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).. Journal of Clinical Oncology. 42(4_suppl). LBA359–LBA359. 22 indexed citations

Lin, Chung‐Wu, Muhammad Adnan Khattak, Thomas Ferguson, et al.. (2024). Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Insights from the Western Australian Context. SHILAP Revista de lepidopterología. 12(10). 257–257. 2 indexed citations

Voss, Martin H., Howard Gurney, Vagif Atduev, et al.. (2024). First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study.. Journal of Clinical Oncology. 42(4_suppl). 2–2. 4 indexed citations

Albigès, Laurence, Howard Gurney, Vagif Atduev, et al.. (2023). Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial. The Lancet Oncology. 24(8). 881–891. 73 indexed citations

Lee, Chung‐Han, Howard Gurney, Vagif Atduev, et al.. (2023). First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.. Journal of Clinical Oncology. 41(16_suppl). 4518–4518. 1 indexed citations

10.

Choueiri, Toni K., Piotr Tomczak, S.H. Park, et al.. (2021). 653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564. Annals of Oncology. 32. S679–S680. 1 indexed citations

11.

Gedye, Craig, David Pook, Laurence E. Krieger, et al.. (2020). UNISON: Nivolumab then ipilimumab + nivolumab in advanced nonclear cell renal cell carcinoma (ANZUP 1602).. Journal of Clinical Oncology. 38(6_suppl). TPS768–TPS768. 1 indexed citations

12.

Willson, Melina L, et al.. (2019). Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews. 61 indexed citations

13.

Khan, Aliya, Anna K. Nowak, Sunil Verma, et al.. (2018). Bisphosphonates for prevention of bone loss in women with early breast cancer. Cochrane Database of Systematic Reviews. 1 indexed citations

14.

Barton, Sarah, Lila Zabaglo, Roger A’Hern, et al.. (2012). Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer. British Journal of Cancer. 106(11). 1760–1765. 50 indexed citations

15.

Larkin, James, et al.. (2010). Symptomatic brain metastases from renal cell carcinoma during treatment with sunitinib or sorafenib.. Journal of Clinical Oncology. 28(15_suppl). e15023–e15023. 2 indexed citations

16.

Khan, Aliya, Anna K. Nowak, Sunil Verma, et al.. (2009). Bisphosphonates for prevention of bone loss in women with early breast cancer. Cochrane Database of Systematic Reviews. 1 indexed citations

17.

Nowak, Anna K., Thomas Ferguson, Nicholas Wilcken, & Davina Ghersi. (2007). A meta-analysis of taxanes in adjuvant chemotherapy (ACT) of early breast cancer (EBC). Journal of Clinical Oncology. 25(18_suppl). 545–545. 3 indexed citations

18.

Ferguson, Thomas, et al.. (2007). Taxanes for adjuvant treatment of early breast cancer. Cochrane Database of Systematic Reviews. 9(4). CD004421–CD004421. 149 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact